Aslan Pharmaceuticals reported preliminary Phase I single-ascending dose data on intravenous ASLAN004 demonstrating the IL13 receptor antibody to be safe and well tolerated in healthy volunteers with no discontinuations due to adverse events, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. ASLAN004 caused complete inhibition of phosphorylation of STAT6 within one hour lasting for greater than 29 days, adds the analyst. He believes these results present the opportunity for once-monthly dosing of ASLAN004 with comparable activity to Regeneron’s (REGN) Dupixent. Tenthoff reiterates an Overweight rating on Aslan Pharmaceuticals with a $7 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.